Who
Stan Smith
Director
Company insider
Files Form 4 as: Director, MAIA Biotechnology.
In numbers
- Trades disclosed
- 88
- Buys
- 51
- Sells
- 0
- Bought
- $3.0M
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 1 Aug 2022
- Last trade
- 30 Sep 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Sep 2026filed 2 Oct 2026 | MAIA MAIA Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,871 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | MAIA MAIA Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,003 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | MAIA MAIA Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,003 at $0.00 | filing |
| 1 Jun 2026filed 2 Jun 2026 | MAIA MAIA BiotechnologyBiotechnology | SEC FORM 4 Bought | $100K75,000 at $1.34 | filing |
| 1 Jun 2026filed 2 Jun 2026 | MAIA MAIA BiotechnologyBiotechnology | SEC FORM 4 Bought | $101K75,000 at $1.34 | filing |
| 31 Mar 2026filed 2 Apr 2026 | MAIA MAIA Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,099 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | MAIA MAIA Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,099 at $0.00 | filing |
| 31 Dec 2025filed 5 Jan 2026 | MAIA MAIA Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,216 at $0.00 | filing |
| 31 Dec 2025filed 5 Jan 2026 | MAIA MAIA Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,216 at $0.00 | filing |
| 22 Dec 2025filed 23 Dec 2025 | MAIA MAIA Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code P | $78K57,189 at $1.36 | filing |
| 22 Dec 2025filed 23 Dec 2025 | MAIA MAIA BiotechnologyBiotechnology | SEC FORM 4 Bought | $70K57,189 at $1.22 | filing |
| 5 Dec 2025filed 9 Dec 2025 | MAIA MAIA BiotechnologyBiotechnology | SEC FORM 4 Bought | $5,4964,580 at $1.20 | filing |
| 5 Dec 2025filed 9 Dec 2025 | MAIA MAIA BiotechnologyBiotechnology | SEC FORM 4 Bought | $5,4504,580 at $1.19 | filing |
| 5 Dec 2025filed 9 Dec 2025 | MAIA MAIA BiotechnologyBiotechnology | SEC FORM 4 Bought | $5,4964,580 at $1.20 | filing |
| 26 Nov 2025filed 1 Dec 2025 | MAIA MAIA BiotechnologyBiotechnology | SEC FORM 4 Bought | $16K15,000 at $1.04 | filing |
| 25 Nov 2025filed 26 Nov 2025 | MAIA MAIA BiotechnologyBiotechnology | SEC FORM 4 Bought | $15K15,000 at $0.98 | filing |
| 24 Nov 2025filed 26 Nov 2025 | MAIA MAIA BiotechnologyBiotechnology | SEC FORM 4 Bought | $9,90010,000 at $0.99 | filing |
| 2 Oct 2025filed 6 Oct 2025 | MAIA MAIA Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,844 at $0.00 | filing |
| 1 Oct 2025filed 2 Oct 2025 | MAIA MAIA Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code P | $30K19,230 at $1.57 | filing |
| 1 Oct 2025filed 2 Oct 2025 | MAIA MAIA BiotechnologyBiotechnology | SEC FORM 4 Bought | $25K19,230 at $1.30 | filing |
News
Why Adidas Stan Smith Sneakers Are Coming Backmarieclaire.com · 8 Sep 2026MAIA Biotechnology (NYSEAMERICAN:MAIA) Shares Up 0.8% – Here's What HappenedMAIA · dailypolitical.com · 8 Oct 2026MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung CancerMAIA · manilatimes.net · 7 Oct 2026
1 headline in the last 90 days name Stan Smith; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.